Supernus, Q4 and Total Revenue

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.
Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
Supernus Pharmaceuticals Inc (SUPN) reports robust revenue growth and strategic advancements, despite facing market challenges and legacy product declines.
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Supernus: Q4 Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and stock option expense, were 75 cents per share.
Supernus Pharmaceuticals (SUPN) to Release Earnings on Tuesday
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes on Tuesday, February 25th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.
Q4 2024 Supernus Pharmaceuticals Inc Earnings Call
Jack Khattar; President, Chief Executive Officer, Secretary, Director; Supernus Pharmaceuticals Inc Timothy Dec; Chief Financial Officer, Senior Vice President; Supernus Pharmaceuticals Inc Good afternoon,
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Supernus Pharmaceuticals (SUPN) reported $174.16 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 6%. EPS of $0.75 for the same period compares to $0.02 a year ago.
Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
pharmaphorum7d
Supernus reports less than super data for depression drug
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
FierceBiotech7d
Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...
Investing23h
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates
The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...